Company intelligence / Profile preview

Eximore

Ownership
Private
Development stage
Phase 1
01

Overview

The company is developing a non-invasive punctal plug drug delivery system that addresses the challenges of eye drops while leveraging the high retention, tolerability, and safety of conventional punctal plugs using nano-particle technology to mold drugs into the actual plug itself.

Therapeutic areas
Ophthalmology
Modalities
Drug-eluting punctal plugsnano-particle technology
Industry
Biotech
02

Drug pipeline

2 assets

EXP-TC

Unknown

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Eximore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eximore.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call